Physicians' Academy for Cardiovascular Education

ESC Heart Failure 2017

PACE-CME.org was present at the ESC Heart Failure congress in Paris (29 April- 2 May). Find reporting material of presented trending heart failure news here.

Meeting Impression: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach

News - May 1, 2017
During a satellite symposium at ESC Heart Failure 2017 in Paris, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.

During a satellite symposium at ESC Heart Failure 2017 in Paris, organised by PACE-CME, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.

Type of glycemic control is more important than tight glycemic control

3' education - May 1, 2017 - ESC HF 2017, Paris
Diabetes worsens risk associated with various CV conditions. Prof. David Fitchett considers the therapeutic options to minimise this CV risk and the increasing role of cardiologists in current optimal management of CV patients with diabetes.

ESC HF 2017 Diabetes worsens risk associated with various CV conditions. Prof. David Fitchett considers the therapeutic options to minimise this CV risk and the increasing role of cardiologists in current optimal management of CV patients with diabetes.

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris
The HeartLogic system combines several parameters including heart sound, respiratory rate and patient activity, into an algorithm that can identify patients at risk of developing HF decompensation. Prof. Cowie discusses how this advances the field and what remains to be done.

ESC HF 2017 The HeartLogic system combines parameters including heart sound, respiratory rate and patient activity, to identify HF patients at risk of developing decompensation. Prof. Cowie discusses what remains to be done to advance the field.

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris
At the ESC HF congress in Paris, professor Voors shares the disappointing results of the RELAX-AHF, in which treatment with serelaxin in acute HF did not result in improvement in mortality and worsening HF

ESC HF 2017 At the ESC HF congress in Paris, professor Voors shares the disappointing results of the RELAX-AHF, in which treatment with serelaxin in acute HF did not result in improvement in mortality and worsening HF

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris
Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

Heart failure is the most disabling and deadly complication of diabetes. Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.

Cardiopoietic stem cell therapy induced left ventricular remodelling

News - May 1, 2017
Data at 52 weeks of the (Congestive Heart Failure Cardiopoietic Regenerative Therapy) CHART-1 study showed changes in LV measures suggestive of a beneficial remodelling effect. The number of injections influenced the changes.

ESC HF 2017 Data at 52 weeks of the CHART-1 study showed changes in LV measures suggestive of a beneficial remodelling effect. The number of injections influenced the changes.

ESC Heart Failure Grand Debate: Vasodilators in acute heart failure

News - May 1, 2017
Milton Packer and Alexandre Mebazaa discussed whether vasodilators have a role in management of Acute HF and why or why not, and what additional options are needed.

ESC HF 2017 Milton Packer and Alexandre Mebazaa discussed whether vasodilators have a role in management of Acute HF and why or why not, and what additional options are needed.

New multisensory telemonitoring device accurately identifies risk of worsening HF

News - May 3, 2017
Based on heart sounds, respiration rate, and volume, thoracic impedance, night heart rate, and daily activity, multisensory telemonitoring device HeartLogic predicts the risk of an HF event independent of baseline variables.

ESC HF 2017 Based on heart sounds, respiration rate, and volume, thoracic impedance, night heart rate, and daily activity HeartLogic predicts the risk of an HF event independent of baseline variables.

Grand Debate on Sacubitril/Valsartan: is it ready to be used as first-line therapy?

News - May 1, 2017

ESC HF 2017 Impression of this new session type, in which John McMurray and Mariell Jessup debated why or why not ARNI should be considered first-line therapy in patients with heart failure.

Reducing heart rate benefits HF patients in sinus rhythm, but not those with AF

News - Apr. 30, 2017
Pooled individual patient data reveal that slowing heart rate with a betablocker lowers mortality in sinus rhythm, while in AF patients baseline or attained heart rate does not affect mortality.

ESC HF 2017 Pooled individual patient data reveal that slowing heart rate with a betablocker lowers mortality in sinus rhythm, while in AF patients baseline or attained heart rate does not affect mortality.

No benefit of heart rate reduction in HFpEF patients

News - Apr. 30, 2017
In EDIFY, treatment with selective inhibitor of the sino-atrial node If current ivabradine for 8 months reduced heart rate, but did not improve E/e’, exercise capacity or NT-proBNP levels in patients with HFpEF.

ESC HF 2017 In EDIFY, treatment with ivabradine for 8 months reduced heart rate, but did not improve E/e’, exercise capacity or NT-proBNP levels in patients with HFpEF.

Acute reversible decline in eGFR seen with SGTL2 inhibitor in T2DM patients with or without HF

News - Apr. 30, 2017
In EMPA-REG OUTCOME, treatment with In EMPA-REG OUTCOME, treatment with empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.In EMPA-REG OUTCOME, treatment with SGTL2 inhibitor empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.

ESC HF 2017 In EMPA-REG OUTCOME, treatment with empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.